期刊文献+

临床药师参与化疗致难治性呕吐的药物治疗案例分析

Case Analysis on Clinical Pharmacists Participating in Drug Treatment of Refractory Vomiting Caused by Chemotherapy
下载PDF
导出
摘要 为探讨临床药师在化疗致难治性呕吐治疗中的作用.在3例病例治疗中,临床药师通过观察患者呕吐的治疗效果及并发的不良反应,协助医师为患者制订个体化给药方案.结果显示,临床药师在患者的诊疗过程中,根据患者的症状,建议医师调整患者的治疗用药,使药品的临床应用更加合理.经过治疗,患者的呕吐得以控制,不良反应也得到缓解.说明抗肿瘤专业临床药师参与临床实践,可从药学角度发挥其优势,优化治疗方案,保证患者用药安全、有效. The reference was provided for clinical pharmacists participating in the treatment of malignant vomiting caused by chemotherapy.During the treatment of 3 cases of chemotherapy-induced nausea,after observing the treatment effect of patients with vomiting and concurrent adverse reactions,clinical pharmacists assisted doctors in formulating individualized dosing plans.The results showed that in the treatment,according to the symptom of the patient,the clinical pharmacists give the suggestion to adjust the relevant treatment drugs so as to get more reasonable application of drugs.After treatment,the vomiting was controlled and the adverse reactions were alleviated.It's proved that the participation of anti-tumor professional clinical pharmacists in clinical practice can give full play to their advantages from the perspective of pharmacy to optimize the treatment plan,and ensure the safe and effective medication of patients.
作者 刘祖祥 屠文莲 段继洪 曹玮 LIU Zuxiang;TU Wenlian;DUAN Jihong;CAO Wei(Department of Pharmacy,The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology,Kunming,Yunnan,China 650032;Department of Clinical Medicine,The First People's Hospital of Jinghong City,Xishuangbanna,Yunnan,China 666100)
出处 《昆明学院学报》 2021年第3期110-113,共4页 Journal of Kunming University
关键词 临床药师 奥氮平 难治性呕吐 药物调整 clinical pharmacists Olanzapine refractory vomiting drug adjustment
  • 相关文献

参考文献13

二级参考文献86

  • 1杨新杰,张树才.雷莫司琼预防肺癌顺铂化疗所致恶心呕吐效果的随机对照临床研究[J].中国肺癌杂志,2005,8(4):322-325. 被引量:13
  • 2谭小林.奥氮平与利司哌酮治疗痴呆病人的精神行为症状的比较[J].中国新药与临床杂志,2006,25(9):703-706. 被引量:4
  • 3陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 4Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy[J]. Expert Opin Pharmacother, 2009, 10(4) :629 -644.
  • 5Licup N. Olanzapine for nausea and vomiting [ J ]. Am J Hosp Palliat Care, 2010,27(6) :432 -434.
  • 6Fountaine RJ, Taylor AE, Mancuso JP, et al. Increased food in- take and energy expenditure following administration of olanzap- ine to healthy men [ J ]. Obesity ( Silver Spring), 2010,18 ( 8 ) : 1646 - 1651.
  • 7Davis MP. The emerging role of palliative medicine in the treat- ment of lung cancer patiems[ J/OL]. Cleve Clin J Med, 2012 [ 2012 -12 -10 ]. http ://www. ncbi. nlm. nih. gov/pubmed/2261 - 4967.
  • 8Passik SD, Navari RM, Jung SH, et al. A phase I trim of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients : a Hoosier Oncology Group study[ J]. Cancer In- vest, 2004,22(3) :383 -388.
  • 9Navari RM, Einhom LH, Passik SD, et al. A phase 11 trim of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study[ J ]. Support Care Cancer, 2005,13 (7) :529 - 534.
  • 10Navari RM, Einhom LH, Loehrer PJ Sr, et al. A phase I1 trial of olanzapine, dexamethasone, and palonosetron for the preven- tion of chemotherapy-induced nausea and vomiting : a Hoosier on- cology group study [ J ]. Support Care Cancer, 2007,15 ( 11 ) : 1285 - 1291.

共引文献496

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部